Login
$SUPN
$28.83 +$0.00 (0.0%) After hours

$SUPN SEC Filings

Filed On Filing
04 Nov 2026 Form 4: Mottola Frank, SVP, Chief Tech. Ops. Officer

Acquired 30,099 shares (Other Transaction) · Acquired 245,643 Employee Stock Option (right to buy) (Other Transaction) · Acquired 186,888 Restricted Stock Units (Other Transaction)

04 Nov 2026 Form 4: Horich William Todd, SVP, Chief Commercial Officer

Acquired 216,381 Employee Stock Option (right to buy) (Other Transaction) · Acquired 190,391 Restricted Stock Units (Other Transaction)

04 Nov 2026 Form 4: Dec Timothy C, SVP, Chief Financial Officer

Acquired 14,059 shares (Other Transaction) · Acquired 396,574 Employee Stock Option (right to buy) (Other Transaction) · Acquired 141,878 Restricted Stock Units (Other Transaction)

04 Nov 2026 Form 4: Barlow Carrolee, Director

Acquired 41,652 shares (Other Transaction) · Acquired 4,603 Restricted Stock Units (Other Transaction) · Acquired 112,384 Director Stock Option (right to buy) (Other Transaction)

04 Nov 2026 Form 4: Bhatt Padmanabh P., SVP of IP, CSO

Acquired 28,702 shares (Other Transaction) · Acquired 82,394 Employee Stock Option (right to buy) (Other Transaction) · Acquired 183,999 Restricted Stock Units (Other Transaction)

04 Nov 2026 Form 4: Sensenig Bethany, Director

Acquired 4,603 Restricted Stock Units (Other Transaction) · Acquired 68,807 Director Stock Option (right to buy) (Other Transaction)

04 Nov 2026 Form 4: Gemayel Georges, Director

Acquired 42,009 shares (Other Transaction) · Acquired 4,603 Restricted Stock Units (Other Transaction) · Acquired 119,215 Director Stock Option (right to buy) (Other Transaction)

04 Nov 2026 Form 4: Khattar Jack A., Director

Acquired 3,413,555 shares (Other Transaction) · Acquired 3,937,295 Employee Stock Option (right to buy) (Other Transaction) · Acquired 1,221,960 Restricted Stock Units (Other Transaction)

04 Nov 2026 Form 4: Rubin Jonathan, SVP, Chief Medical Officer

Acquired 21,529 shares (Other Transaction) · Acquired 221,002 Employee Stock Option (right to buy) (Other Transaction) · Acquired 135,333 Restricted Stock Units (Other Transaction)

04 Nov 2026 Form 3: Gemayel Georges, Director

No securities owned

04 Nov 2026 Form 3: Sensenig Bethany, Director

No securities owned

04 Nov 2026 Form 3: Khattar Jack A., Director

No securities owned

04 Nov 2026 Form 3: Rubin Jonathan, SVP, Chief Medical Officer

No securities owned

04 Nov 2026 Form 3: Horich William Todd, SVP, Chief Commercial Officer

No securities owned

04 Nov 2026 Form 3: Mottola Frank, SVP, Chief Tech. Ops. Officer

No securities owned

04 Nov 2026 Form 3: Dec Timothy C, SVP, Chief Financial Officer

No securities owned

04 Nov 2026 Form 3: Bhatt Padmanabh P., SVP, Chief Scientific Officer

No securities owned

04 Nov 2026 Form 3: Barlow Carrolee, Director

No securities owned

03 Nov 2026 8-K: Other Events

Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “Indenture”), go...

02 Nov 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more

Anti-Corruption Laws, Anti-Money Laundering Laws, Export Controls and Sanctions

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support